| |
 |
| Joan
Provizer, Robert Kacick and Carol Feghali-Bostwick,
Ph.D. |
Two
chapter board members and a researcher who sat on the Foundation’s
peer review committee have been selected to join the Scleroderma
Foundation’s Board of Directors. Joan Provizer, of Michigan,
and Robert Kacick of Chicago along with Carol Feghali-Bostwick,
Ph.D., were appointed at the board’s December meeting.
Their three-year terms take effect Jan. 1, 2007.
|
 |
|
SILVER
SPRING, Md. and SATELLITE BEACH, Fla., Dec. 12 /PRNewswire-FirstCall/
-- Lung Rx, Inc., a wholly-owned subsidiary of United Therapeutics
Corporation (Nasdaq: UTHR), announced that its Canadian affiliate,
Northern Therapeutics, Inc., has commenced the first-ever
human trial of a novel, cell-mediated gene therapy for the
treatment of pulmonary arterial hypertension. |
|
|
ALLSCHWIL,
SWITZERLAND – 11 December 2006 – Actelion Ltd
(SWX: ATLN) announced today that it has initiated a comprehensive
Phase III program for Actelion-1, the first tissue targeting
endothelin receptor antagonist (ERA). Initially, development
will focus on pulmonary hypertension (PH), with other cardiopulmonary
indications expected to follow. |
|
|
The clock is ticking on the time left in the year to make
a tax deductible contribution to the Scleroderma Foundation.
Since this is the giving season, there has never been a better
time to give to the organization that supports scleroderma
patients and their families with support program, educational
initiatives and research grants. |
|
|
The "Scleroderma Voice" #4 featured a story on Tom
Tyler, a former cowboy movie star and U.S. Olympian in the
first half of the 20th century who died from scleroderma.
|
|
